Pharmaceutical formulations for sustained release

• US 20060293217A1
• Filed: 08/15/2005
• Published: 12/28/2006
• Est. Priority Date: 03/19/2001
• Status: Abandoned Application

• Current Assignee: Praecis Pharmaceuticals, Inc. (GSK plc)
• Original Assignee: Praecis Pharmaceuticals, Inc. (GSK plc)
• Inventors: Barker, Nicholas, Wolfe, Janet L.
• Application Number:
  US11/205,296
• Publication Number:
  US 20060293217A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof

Abstract

Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged periods of time, e.g., one month, after administration. Methods for preparing these pharmaceutical compositions, as well as methods of using them to treat a subject are also provided.

Claims

1. A pharmaceutical composition comprising a solid ionic complex, said complex comprising a pharmaceutically active compound and an ionic macromolecule.

2. The pharmaceutical composition of claim 1 wherein the pharmaceutically active compound has a net positive charge.

3. The pharmaceutical composition of claim 2, wherein the pharmaceutically active compound has at least one functional group selected from the group consisting of primary amino groups, secondary amino groups, tertiary amino groups, imino groups, quaternary ammonium groups, amidino groups, guanidino groups, phosphonium groups and sulfonium groups.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutically active compound has a net negative charge.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutically active compound has at least one functional group selected from the group consisting of carboxylate groups, sulfonate groups, phosphonate groups, sulfamate groups, sulfate ester groups, phosphate ester groups, sulfinate groups, phosphinate groups, carbonate groups, thiocarboxylate groups and carbamate groups.

6. The pharmaceutical composition of claim 2, wherein the pharmaceutically active compound contains at least one functional group selected from the group consisting of primary amino groups, secondary amino groups, tertiary amino groups, imino groups and quaternary ammonium groups.

8. The pharmaceutical composition of claim 1, wherein the pharmaceutically active compound has a molecular weight of about 1000 amu or less.

11. The pharmaceutical composition of claim 2, wherein the pharmaceutically active compound has a net charge of at least +1.

13. The pharmaceutical composition of claim 4, wherein the pharmaceutically active compound has a net charge of at least −

1.

15. The pharmaceutical composition of claim 1, wherein the ionic macromolecule comprises at least one functional group selected from the group consisting of carboxylic acid, sulfonic acid, sulfamic acid, primary amine, secondary amine, tertiary amine, quaternary ammonium, guanidino and amidino.

16. The pharmaceutical composition of claim 4, wherein the ionic macromolecule is a polypeptide or a polysaccharide.

17. The pharmaceutical composition of claim 1, wherein a single dose of the solid ionic complex provides sustained delivery of the pharmaceutically active compound to a subject for at least one week after the pharmaceutical composition is administered to the subject.

23. The pharmaceutical composition of claim 1, wherein the pharmaceutically active compound content of the solid ionic complex is at least 50% by weight.

28. The pharmaceutical composition of claim 1, wherein the pharmaceutically active compound and the ionic macromolecule used to form the solid ionic complex are combined at a weight ratio of ionic macromolecule:

pharmaceutically active compound of 1;

1 to 0.1;

1

29. The pharmaceutical composition of claim 1, wherein the solid ionic complex is not a microcapsule.

30. A packaged formulation for treating a subject for a condition treatable with a pharmaceutically active compound, comprising the pharmaceutical composition of claim 1 packaged with instructions for using the composition for treating a subject having a condition treatable with a pharmaceutically active compound.

31. A method for treating a subject for a condition treatable with a pharmaceutically active compound, comprising administering to the subject the pharmaceutical composition of claim 1.

7. (canceled)

9-10. -10. (canceled)

12. (canceled)

14. (canceled)

18-22. -22. (canceled)

24-27. -27. (canceled)

32. A method for preparing a pharmaceutical formulation, comprising:

providing a pharmaceutically active compound and an ionic macromolecule;

combining the pharmaceutically active compound and the ionic macromolecule under conditions such that a solid ionic complex of the pharmaceutically active compound and the ionic macromolecule forms; and

preparing a pharmaceutical formulation comprising the solid ionic complex.

33-39. -39. (canceled)